Agilent, NeoGenomics, and Labcorp Turn Distribution Into the Battleground
Agilent, NeoGenomics, and Labcorp show how diagnostics competition is shifting toward the platforms and networks that control adoption, workflow, and monetization.
Updated
What is this trend?
Diagnostics leaders are competing to own the distribution layer—platforms, networks, and channels that decide which assays, AI tools, and workflows get adopted and monetized.
- Acquisitions are shifting from instruments to software, data, and workflow control.
- Vendor-neutral platforms are becoming the preferred way to scale AI and third-party tests.
- Multi-site lab networks are valuable because they steer adoption across large patient bases.
- Recurring informatics revenue is now part of the diagnostics value stack.
- Distribution access is emerging as the main moat in specialty diagnostics.
What’s the latest?
How it developed
- Companion diagnostics become commercial platforms, FDA makes AI validation the moat, and pathology consolidates
- Pathology Platforms Are Consolidating Into Operating Layers
Go deeper
Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.
